World Journal of Gastroenterology - Baishideng Publishing Group

BPG is committed to discovery and dissemination of knowledge

Cited by in CrossRef

For:	Wang LF, Chen PR, He SK, Duan SH, Zhang Y. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review. World J Gastroenterol 2023; 29(29): 4481-4498 [PMID: 37621757 DOI: 10.3748/wjg.v29.i29.4481]
URL:	https://www.wjgnet.com/1007-9327/full/v29/i29/4481.htm

(167) (179) (0) (0) (0) (6) (8995) (29)

Number	Citing Articles
1	Yue Yang, Kan-Zuo Fu, Gu Pan. Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis. World Journal of Gastrointestinal Surgery 2024; 16(1): 228-238 doi: 10.4240/wjgs.v16.i1.228 Abstract(792) \| Core Tip(786) \| Full Article(HTML)(2787) \| Full Article (PDF)-3033K(228) \| Full Article with Cover (PDF)-3312K(195) \| Full Article (Word)-1272K(50) \| Full Article (XML)-117K(140) \| Audio-338K(26) \| Peer-Review Report-177K(144) \| Answering Reviewers-115K(134) \| Supplementary Material-213K(133) \| Times Cited (14) \| Total Visits (4428) \| Open
2	Isabelle Whittle, Eva Brown Hajdukova, Hannah Coles, Natasha Perry, Lisa Perrett, Richard Perry, Kyran Jones. Understanding Patient Preferences on Inflammatory Bowel Disease Treatment Modalities and Outcomes: A Global Targeted Literature Review. Advances in Therapy 2026; 43(6) doi: 10.1007/s12325-026-03565-9
3	M. Hupé, A. Abdelmoula, T. Chateau, S. Pestour, X. Roblin, C. Gay, G. Boschetti, S. Nancey, N. Mathieu. Impact of immediate drug optimization of ustekinumab on medium term targets in Crohn’s disease: results from the multicentre retrospective real-life study MUST. Digestive and Liver Disease 2025; 57(9) doi: 10.1016/j.dld.2025.05.024
4	Shi-Yan Zhang. Navigating new horizons in inflammatory bowel disease: Integrative approaches and innovations. World Journal of Gastroenterology 2024; 30(41): 4411-4416 doi: 10.3748/wjg.v30.i41.4411 Abstract(717) \| Core Tip(697) \| Full Article(HTML)(2451) \| Full Article (PDF)-371K(189) \| Full Article with Cover (PDF)-1855K(215) \| Full Article (XML)-84K(118) \| Audio-1001K(13) \| Peer-Review Report-176K(126) \| Answering Reviewers-400K(254) \| Times Cited (2) \| Total Visits (2973) \| Open
5	Junya Shiota, Moto Kitayama, Hiroko Inomata, Taro Akashi, Maiko Tabuchi, Keiichi Hashiguchi, Kayoko Matsushima, Yuko Akazawa, Naoyuki Yamaguchi, Hisamitsu Miyaaki. Upadacitinib Treatment Outcomes in Crohn’s Disease: A Retrospective Analysis of Clinical Response and Perianal Fistula Resolution. Inflammatory Intestinal Diseases 2026; 11(1) doi: 10.1159/000550543
6	Simona Grad, Radu A. Farcas, Dan L. Dumitrascu, Teodora Surdea-Blaga, Abdulrahman Ismaiel, Stefan Popa. Predictors of Immunogenicity and Loss of Response to ANTI-TNFα Therapy in Crohn Disease—A Systematic Review. American Journal of Therapeutics 2025; 32(3) doi: 10.1097/MJT.0000000000001867
7	Moushira Zaki, Hisham A. Orban, Marwa Mahmoud, Eman R. Youness, Hoda F. Booles, Wagdy K. B. Khalil, Wafaa Wafy, Kamal A. El-Atrebi, Khaled Hamed, Hala T. El-Bassyouni. Evaluation of adropin, fibroblast growth factor-1 (FGF-1), and Toll-like receptor-1 (TLR1) biomarkers in patients with inflammatory bowel disease: gene expression of TNF-α as a marker of disease severity. Egyptian Journal of Medical Human Genetics 2024; 25(1) doi: 10.1186/s43042-024-00533-2
8	Jiaxin Shen, Xing Yu, Jinni Xu, Zhihua Zheng, Weiwei Zheng. Characteristics of the Tongue Coating Microbiome and Its Subtype Differences in Patients with Inflammatory Bowel Disease. Microorganisms 2026; 14(6) doi: 10.3390/microorganisms14061381
9	Konstantinos C. Mpakogiannis, Paraskevi Chasani, Ioanna Nefeli Mastorogianni, Konstantinos H. Katsanos, Fotios S. Fousekis. Predictors of First Anti-TNF Treatment Failure in Patients with Inflammatory Bowel Disease: A Single-Center Cohort Study. Biomedicines 2026; 14(5) doi: 10.3390/biomedicines14050984
10	Julia López De-La-Cruz, Fernando Gomollón, Javier Louro, Juan López Pérez, María Mercedes Nocito Colon, Beatriz Gallego Llera, Sandra García-Mateo, Samuel J Martínez-Domínguez, María Concepción Aso Gonzalvo, Carla J Gargallo-Puyuelo. Impact of HLADQA105 and HLADQA103 on Safety and Loss of Response to Anti-Tumor Necrosis Factor in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2025; 19(6) doi: 10.1093/ecco-jcc/jjae178
11	Ahmad K. Al-Jalehawi, Samer Imad Mohammed. Clinical use of tumor necrosis factor-alpha inhibitors in Iraq: a review of their documented efficacy, safety, and associated genetics. Review of Clinical Pharmacology and Pharmacokinetics - International Edition 2024; 38(3) doi: 10.61873/SEZR6390
12	Cody S Howe, Marina Chulkina, Ryan Syrcle, Christina McAninch, Steven McAninch, Irina V Pinchuk, Ellen J Beswick. MK2 Inhibition in CD4+ T Cells Protects Against IFNγ and IL-17A, Chronic Inflammation, and Fibrosis in Inflammatory Bowel Disease Models. Inflammatory Bowel Diseases 2025; 31(6) doi: 10.1093/ibd/izaf026
13	José Luis Rueda García, Cristina Suárez-Ferrer, Clara Amiama Roig, Laura García Ramírez, Cristina García Rojas, Eduardo Martín-Arranz, Joaquín Poza Cordón, María Sánchez Azofra, Jesús Noci, Cristina Cubillo García, María Dolores Martín-Arranz. Association of early therapeutic drug monitoring of adalimumab with biologic remission and drug survival in Crohn’s Disease. Therapeutic Advances in Gastroenterology 2025; 18 doi: 10.1177/17562848251324226
14	Qinhui Tang, Xiaowei Tang, Wenmeng Yin, Yantong Li, Xiaolin Zhong, Vinay Kumar. Infective pneumonia following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: A real-world disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database. PLOS One 2025; 20(8) doi: 10.1371/journal.pone.0317242
15	Ji-Eun Na, Yong-Eun Park, Jong-Ha Park, Tae-Oh Kim, Jong-Yoon Lee, Jong-Hoon Lee, Su-Bum Park, Seung-Bum Lee, Seung-Min Hong. Efficacy of Second-Line Biological Therapies in Moderate to Severe Ulcerative Colitis Patients with Prior Failure of Anti-Tumor Necrosis Factor Therapy: A Multi-Center Study. Journal of Personalized Medicine 2024; 14(10) doi: 10.3390/jpm14101066
16	Xiaoyu Cai, Yao Yao, Yongquan Zheng, Xuezhi Zhao. Multi-omics gut microbiome signatures for treat-to-target management in inflammatory bowel disease. Microbiological Research 2026; 309 doi: 10.1016/j.micres.2026.128511
17	Nikil Vootukuru, Abhinav Vasudevan. Approach to loss of response to advanced therapies in inflammatory bowel disease. World Journal of Gastroenterology 2024; 30(22): 2902-2919 doi: 10.3748/wjg.v30.i22.2902 Abstract(813) \| Core Tip(967) \| Full Article(HTML)(5307) \| Full Article (PDF)-790K(333) \| Full Article with Cover (PDF)-1040K(410) \| Full Article (XML)-442K(150) \| Audio-825K(45) \| Peer-Review Report-251K(127) \| Answering Reviewers-490K(125) \| Times Cited (12) \| Total Visits (7205) \| Open
18	Chun-xiu Xiao, Wen-yuan Wu, Shi-cong Li, Mei-ling Dong, Yu-hang Bian, Meng Yu, Xiang Lv, Wei-guo Chen, Min Hong, Jing Zhou, Yang Sun, Hong-yue Ma, Yu-yu Zhu. 5-OH-TMT mitigates colitis through HTRA2 binding–mediated activation of the Dectin-1 signaling pathway. Acta Pharmacologica Sinica 2026; doi: 10.1038/s41401-026-01782-0
19	Xin Gao, Cui Zhang, Zeman Zhao, Yujie Chen, Hehua Lei, Zheng Cao, Wenkai Yu, Weichuan Lin, Yanmeng He, Xinzhi Li, Qingwei Xiang, Zhiwen Zhang, Limin Zhang, Gang Chen. Ophiopogon japonicus Polysaccharides Promote Microbial Production Of Chenodeoxycholic Acid To Alleviate Ulcerative Colitis in Mice by Inhibiting the STING1-Related NF-κB Pathway. Journal of Agricultural and Food Chemistry 2026; 74(15) doi: 10.1021/acs.jafc.5c14733
20	Yi-mei Chen, Qi-wen Xiao, Yong-jie Shi, Shao-na Zeng, Hong-yun Jia, Xun Zheng, Si-cong Huang. Targeting IRF5 enhances S100A9-mediated granulocytic MDSC accumulation and suppressive function: a novel therapeutic strategy for ulcerative colitis. International Immunopharmacology 2026; 181 doi: 10.1016/j.intimp.2026.116733
21	Maximilian Berlet, Kamacay Cira, Alissa Jell, Christian Stoess, Helmut Friess, Dirk Wilhelm, Daniel Reim, Marie-Christin Weber, Philipp-Alexander Neumann. Trends in surgical treatment for ulcerative colitis in the era of biologics – A population-based study using German diagnosis-related groups data. Surgery 2025; 185 doi: 10.1016/j.surg.2025.109511
22	Maxwell A. Barffour, Elizabeth Karanja, Mustafa Gandhi, Susan S. Kais, Saurabh Kapur, Yezaz A. Ghouri. Serum or Plasma Oncostatin M for Predicting Primary Non-Response to Tumor Necrosis Factor-α Antagonist Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Clinics and Practice 2026; 16(7) doi: 10.3390/clinpract16070124
23	Hannah Cruz, Prarthna Shah, Nicholas Wohlgemuth, Robert Ketchum, Imad Nassif, Chien-An A. Hu. Pyroptosis in ulcerative colitis: biomarkers and therapeutic targets. Journal of Biomedical Science 2025; 32(1) doi: 10.1186/s12929-025-01206-x
24	Juan Sebastián Frías Ordoñez, Luis Jorge Lombana Amaya, Hernando Marulanda Fernandez, William Otero-Regino. Inhibidores del factor de necrosis tumoral y riesgo de cáncer anorrectal en pacientes con enfermedad inflamatoria intestinal: ¿es acaso una relación constante y peligrosa?. Revista colombiana de Gastroenterología 2026; 41(1) doi: 10.22516/25007440.1303
25	Dongyuan Zheng, Qinke Xu, Jin Wu, Zhouyue Gu, Jieya Chen, Yingchao Liu. Prevalence and bidirectional association between primary sclerosing cholangitis and Crohn's disease: A systematic review and meta-analysis. Gastroenterología y Hepatología (English Edition) 2025; 48(8) doi: 10.1016/j.gastre.2025.502346
26	Dongyuan Zheng, Qinke Xu, Jin Wu, Zhouyue Gu, Jieya Chen, Yingchao Liu. Prevalence and bidirectional association between primary sclerosing cholangitis and Crohn's disease: A systematic review and meta-analysis. Gastroenterología y Hepatología 2025; 48(8) doi: 10.1016/j.gastrohep.2025.502346